Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | INMT | O95050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclocreatine SCHEMBL450343 | 0.82 | CYP2D6 (0.39) | KMT2ATSHRINMT | |
| SCHEMBL19719147 | 0.81 | — | — | |
| Cyclocreatine SCHEMBL11796002 | 0.81 | CYP2D6 (0.38) | KMT2ATSHRINMT | |
| SCHEMBL14511682 | 0.80 | MEN1 (0.31) | KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL16219345 | 0.80 | ALDH1A1 (0.35) | KMT2ARAB9ATSHRMEN1SMN1; SMN2 | |
| SCHEMBL6877063 | 0.80 | KMT2A (0.42) | BDKRB2KMT2ARAB9AMEN1FAAH | |
| Cyclocreatine SCHEMBL1980714 | 0.79 | CYP2D6 (0.37) | KMT2ATSHRINMT | |
| Cyclocreatine SCHEMBL1981687 | 0.75 | INMT (0.40) | KMT2ATSHRINMT | |
| Cyclocreatine SCHEMBL936945 | 0.73 | TSHR (0.33) | KMT2ATSHR | |
| SCHEMBL1710152 | 0.72 | ALDH1A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3988108-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | Rhythm Pharmaceuticals, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3539551-B1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | RHYTHM PHARMACEUTICALS INC (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3539551-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | Rhythm Pharmaceuticals, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| EP-2797615-B1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | RHYTHM PHARMACEUTICALS INC (US) | 2019-04-03 | — | — | EP | disclosed |
| US-9845339-B2 | Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers | RHYTHM PHARMACEUTICALS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20140329743-A1 | Method of Treating Melanocortin-4 Receptor-Associated Disorders in Heterozygous Carriers | RHYTHM PHARMACEUTICALS, INC. | 2014-11-06 | — | — | US | disclosed |
| WO-2013102047-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | RHYTHM PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-20070123453-A1 | Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion | ELI LILLY AND COMPANY | 2007-05-31 | — | — | US | disclosed |
| US-20070105759-A1 | Melanocortin receptor 4 (mc4) agonists and their uses | ELI LILLY AND COMPANY (US) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105759-A1 | Melanocortin receptor 4 (mc4) agonists and their uses | MC4R, MC3R, MC1R | BDKRB2 152/4885KMT2A 2889/4885RAB9A 2292/4885 |
| US-20140329743-A1 | Method of Treating Melanocortin-4 Receptor-Associated Disorders in Heterozygous Carriers | MC4R, MC1R, MC2R | BDKRB2 173/4885KMT2A 1451/4885RAB9A 2765/4885 |
| US-20070123453-A1 | Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion | MC4R, MC5R, MC3R | BDKRB2 126/4885KMT2A 913/4885RAB9A 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.